Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Invested Capital: 2009-2025

Historic Invested Capital for Amicus Therapeutics (FOLD) over the last 16 years, with Sep 2025 value amounting to $622.4 million.

  • Amicus Therapeutics' Invested Capital rose 9.52% to $622.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $622.4 million, marking a year-over-year increase of 9.52%. This contributed to the annual value of $584.2 million for FY2024, which is 6.59% up from last year.
  • Amicus Therapeutics' Invested Capital amounted to $622.4 million in Q3 2025, which was up 4.50% from $595.6 million recorded in Q2 2025.
  • Amicus Therapeutics' Invested Capital's 5-year high stood at $765.3 million during Q3 2021, with a 5-year trough of $495.2 million in Q1 2023.
  • Over the past 3 years, Amicus Therapeutics' median Invested Capital value was $548.0 million (recorded in 2023), while the average stood at $551.9 million.
  • In the last 5 years, Amicus Therapeutics' Invested Capital increased by 18.78% in 2021 and then slumped by 31.55% in 2022.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Invested Capital stood at $696.7 million in 2021, then dropped by 26.08% to $515.0 million in 2022, then increased by 6.41% to $548.0 million in 2023, then increased by 6.59% to $584.2 million in 2024, then increased by 9.52% to $622.4 million in 2025.
  • Its Invested Capital was $622.4 million in Q3 2025, compared to $595.6 million in Q2 2025 and $584.3 million in Q1 2025.